Quantifying Genetic Stability and Quality Control of Multiple Integrations of Orthogonal Transposases

Discover a groundbreaking webinar delving into transposase-mediated genome engineering, genetic quality control (QC) and stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology. Genes encoding biotherapeutic proteins can stably be introduced into mammalian genomes by several different approaches. The transposon-based platform avoids major challenges presented by random integration or viral-based delivery systems.

Here the experts from ATUM will demonstrate how they can use the Leap-In Transposase® technology to genetically engineer Chinese hamster ovary cells (CHO) cells multiple times to manipulate and control their expression profile. By sequentially using three different and orthogonal Leap-In Transposase® enzymes, they have generated a panel of CHO cell lines where they modulate their metabolism to aid selection, integrate a biotherapeutic protein and modify its glycosylation profile to produce stable and high-expressing cell lines with a desired product quality attributes.

To ensure that each transposon is integrated correctly and to demonstrate its orthogonality, they have performed genetic QC by means of Targeted Locus Amplification (TLA) coupled with next-generation sequencing (NGS). This allowed for the identification and genetic characterization of all integration sites of each transposon. Furthermore, by comparing the TLA data of different timepoints they were able to evaluate the genetic stability and integrity of the transposons.

Join this webinar to learn about transposase-mediated genome engineering, genetic quality control and ensuring the genetic stability of orthogonal transposons in the generation of cell lines with Leap-In Transposase® technology.

Speakers

Maya Wright Clark, PhD, Sales and Account Manager, Cergentis

Maya Wright Clark is an Account Manager at Cergentis who holds a PhD in Molecular Cardiology. Her work focused on studying the molecular mechanisms driving hypertrophic cardiomyopathy in in vitro and in vivo models. Her scientific background is brought to her role at Cergentis as she enjoys discussing project details and brainstorming different approaches to challenging requests.

Message Presenter

Mário Pereira, Director of Technologies and Business Development, ATUM

Mario Pereira is a Director of Technologies and Business Development at ATUM and has 14+ years of academic and industrial experience in the field of recombinant protein expression. Mario completed his PhD in Biotechnology at the University of Manchester, where he studied the underlying transcriptional mechanisms regulating recombinant promoters in CHO cells. Following his PhD, Mario continued his passion for bioprocessing at FUJIFILM Diosynth Biotechnologies and Horizon Discovery, where he had different scientific and commercial-related roles, most notably as a Senior Scientist and Strategic Account Manager for Horizon’s CHO-GS platform.

Message Presenter